<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>It is now conceivable that <z:e sem="disease" ids="C0598766" disease_type="Neoplastic Process" abbrv="">leukemogenesis</z:e> requires two types of mutations, class I and class II mutations </plain></SENT>
<SENT sid="1" pm="."><plain>We previously established a mouse bone marrow-derived HF6, an IL-3-dependent cell line, that was immortalized by a class II mutation MLL/SEPT6 and can be fully transformed by class I mutations such as FLT3 mutants </plain></SENT>
<SENT sid="2" pm="."><plain>To understand the molecular mechanism of <z:e sem="disease" ids="C0598766" disease_type="Neoplastic Process" abbrv="">leukemogenesis</z:e>, particularly progression of <z:hpo ids='HP_0002863'>myelodysplastic syndrome</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>) to <z:hpo ids='HP_0002488'>acute leukemia</z:hpo>, we made cDNA libraries from the samples of patients and screened them by expression-cloning to detect class I mutations that render HF6 cells factor-independent </plain></SENT>
<SENT sid="3" pm="."><plain>We identified RasGRP4, an activator of Ras, as a candidate for class I mutation from three of six patients (<z:e sem="disease" ids="C1301355" disease_type="Neoplastic Process" abbrv="">MDS/MPD</z:e> = 1, <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>-RA = 1, <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>/<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e> = 2, CMMoL/<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e> = 1 and <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e>-M2 = 1) </plain></SENT>
<SENT sid="4" pm="."><plain>To investigate the potential roles of RasGRP4 in <z:e sem="disease" ids="C0598766" disease_type="Neoplastic Process" abbrv="">leukemogenesis</z:e>, we tested its in vivo effect in a mouse bone marrow transplantation (BMT) model </plain></SENT>
<SENT sid="5" pm="."><plain>C57BL/6J mice transplanted with RasGRP4-transduced primary bone marrow cells died of T cell <z:hpo ids='HP_0001909'>leukemia</z:hpo>, myeloid <z:hpo ids='HP_0001909'>leukemia</z:hpo>, or myeloid <z:hpo ids='HP_0001909'>leukemia</z:hpo> with T cell <z:hpo ids='HP_0001909'>leukemia</z:hpo> </plain></SENT>
<SENT sid="6" pm="."><plain>To further examine if the combination of class I and class II mutations accelerated leukemic transformation, we performed a mouse BMT model in which both AML1 mutant (S291fsX300) and RasGRP4 were transduced into bone marrow cells </plain></SENT>
<SENT sid="7" pm="."><plain>The double transduction led to early <z:hpo ids='HP_0003674'>onset</z:hpo> of T cell <z:hpo ids='HP_0001909'>leukemia</z:hpo> but not of <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e> in the transplanted mice when compared to transduction of RasGRP4 alone </plain></SENT>
<SENT sid="8" pm="."><plain>Thus, we have identified RasGRP4 as a gene potentially involved in <z:e sem="disease" ids="C0598766" disease_type="Neoplastic Process" abbrv="">leukemogenesis</z:e> and suggest that RasGRP4 cooperates with AML1 mutations in T cell <z:e sem="disease" ids="C0598766" disease_type="Neoplastic Process" abbrv="">leukemogenesis</z:e> as a class I mutation </plain></SENT>
</text></document>